- Home
- SRZN vs TARA Comparison
SRZN vs TARA Comparison
Compare SRZN & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | TARA |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | 44 | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.9M | 268.5M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SRZN | TARA |
|---|---|---|
| Price | $28.66 | $5.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $38.00 | $23.60 |
| AVG Volume (30 Days) | 115.4K | ★ 523.4K |
| Earning Date | 05-08-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | $75.35 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.11 | $2.77 |
| 52 Week High | $33.96 | $7.82 |
Technical Indicators
Market Signals| Indicator | SRZN | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 46.37 |
| Support Level | $23.95 | $4.92 |
| Resistance Level | $29.18 | $5.44 |
| Average True Range (ATR) | 2.42 | 0.25 |
| MACD | -0.05 | 0.04 |
| Stochastic Oscillator | 38.27 | 41.54 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-8141(for wet AMD, DME), SZN-413( For retinopathies) and SZN-8143 (for wet AMD, DME, UME).
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).